Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its segments include oncology and ophthalmology. The oncology segment focuses on the research and development of precision immuno-oncology agents for the treatment of cancer. The ophthalmology segment focuses on research and development of ophthalmologic indications such as wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. VIS-101 targets VEGF-A and ANG-2 to provide more potent treatment benefits for patients with wet AMD and DME.
Back to dashboard
Company Information
About this company
Key people
Wei Fu
Executive Chairman of the Board
Xi-Yong Fu
Director
Ian Ying Woo
Director
Chun Kwok Au
Independent Director
Robert Lenz
Independent Director
Xin Liu
Independent Director
Mark Hagler
President, Chief Commercial Officer
Srishti Gupta
Chief Executive Officer, Director
Emmett T. Cunningham
Vice Chairman of the Board
Ming Lei
Chief Financial Officer
Cong Xu
Senior Vice President - Clinical Development
Liwei Lin
General Counsel and Board Secretary
Sean Wuxiong Cao
Chief Business Development Officer, Director
Phillip Dennis
Chief Medical Officer
Click to see more
Key facts
- Shares in issue6.62m
- EPICNBP
- ISINUS44975P1030
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$204.70m
- Employees30
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.